Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology wilms tumor: A Children's Oncology Group AREN0532 and AREN0533 study report
behalf of the AREN0532 and AREN0533 study committees.
Dive into the research topics of 'Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology wilms tumor: A Children's Oncology Group AREN0532 and AREN0533 study report'. Together they form a unique fingerprint.